To the Editor: The relationship between obesity and more severe disease in patients with coronavirus disease (COVID‐19) is intriguing. Recent articles published in Obesity (1, 2, 3) discuss the possible effects of increased proinflammatory cytokines and disturbances of lung function in people with obesity, but we believe that they overlook an important player in this scenario, which is endothelial dysfunction.
Endothelial dysfunction is present in obesity and is indeed a final common pathway of a cluster of comorbidities, such as hypertension, diabetes, and dyslipidemia. In obesity, the severity of endothelial dysfunction correlates with the degree of visceral adiposity, and studies have indicated the roles of proinflammatory factors and oxidative stress (3). In addition to that chronic scenario, acute endothelial damage occurs, induced by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (which binds to the transmembrane angiotensin‐converting enzyme II receptor). Vascular endothelial cell apoptosis ensues and, in conjunction with the acute “cytokine storm,” promotes the settings for lung microvascular dysfunction, vascular leakage, alveolar edema, and ultimately hypoxia. Proinflammatory cytokines also increase the expression of adhesion molecules, resulting in endothelial activation and procoagulant changes, worsening microvascular flow and tissue perfusion (4). In this context, the acronym “MicroCLOTS” (microvascular COVID‐19 lung vessels obstructive thromboinflammatory syndrome) was recently suggested to describe a progressive endothelial pulmonary syndrome with microvascular thrombosis (5).
Therefore, we believe that among several possible pathophysiologic mechanisms leading to adverse prognosis in people with obesity and COVID‐19, endothelial dysfunction is a central one, as it combines the effects of obesity and its associated comorbidities with the acute effect of SARS‐CoV‐2. This should turn our attention to the endothelium; if we overlook that, we may be overlooking important plausible biological mechanisms underlying the association between obesity and more serious COVID‐19 outcomes.
Disclosure: The authors declare no conflict of interest.
References
- 1. Malavazos AE, Massimiliano M, Romanelli C, Bandera F, Iacobellis G. Targeting the adipose tissue in COVID‐19. Obesity (Silver Spring) 2020;28:1178‐1179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Jose RJ, Manuel A. Does COVID‐19 disprove the obesity paradox in ARDS? Obesity (Silver Spring) 2020;28:1007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Kruglikov IL, Scherer PE. The role of adipocytes and adipocyte‐like cells in the severity of COVID‐19 infections. Obesity (Silver Spring) 2020;28:1187‐1190. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Moore BJB, June CH. Cytokine release syndrome in severe COVID‐19. Science 2020;368:473‐474. [DOI] [PubMed] [Google Scholar]
- 5. Ciceri F, Beretta L, Scandroglio AM, et al. Microvascular COVID‐19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc 2020;22:95‐97. [DOI] [PMC free article] [PubMed] [Google Scholar]